BetterLife Pharma IncCanadian Securities Exchange:BETRView on OTCQB
- LAST PRICE0.1150
- TODAY'S CHANGE (%)-0.0100 (-8.0000%)
- Bid / Lots0.1200/ 15
- Ask / Lots0.1250/ 51
- Open / Previous Close0.1250 / 0.1250
- Day Range
- 52 Week Range
- Volume14,885
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BETR |
|---|---|---|
| 09:32 ET | 5500 | 0.125 |
| 12:46 ET | 6500 | 0.11 |
| 12:51 ET | 2500 | 0.115 |
Oct 23, 2024
BetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001, from 8:00AM ET on Wednesday Oct 23, 2024 by Dow Jones
8:00AM ET on Wednesday Oct 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BetterLife Pharma Inc | 16.2M | -2.7x | --- |
Sirona Biochem Corp | 17.0M | -6.2x | --- |
Quantum BioPharma Ltd | 12.6M | -0.4x | --- |
Biovaxys Technology Corp | 18.3M | -2.4x | --- |
Pharmala Biotech Holdings Inc | 14.6M | -22.8x | --- |
Telo Genomics Corp | 11.2M | -3.9x | --- |
Company Information
BetterLife Pharma Inc. is a biotechnology company. The Company is primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical and is a non-hallucinogenic and non- controlled lysergic acid diethylamide (LSD) derivative in development and that is unregulated and therefore can be self-administered. Its synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical and is based on honokiol, the active anxiolytic ingredient of magnolia bark. Its pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency. It also owns a drug candidate for the treatment of viral infections.
Contact Information
- Headquarters
- 1275 WEST 6TH AVENUEVANCOUVER, BC, Canada V6H 1A6
- Phone
- 438-884-8841
- Fax
- 604-551-5178
Executives
- Chairman of the Board, Chief Executive Officer
- Ahmad Doroudian
- Chief Financial Officer
- Moira Ong
- Chief Operating Officer
- Hooshmand Sheshbaradaran
- Independent Director
- Robert Metcalfe
- Independent Director
- Ralph Pullen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 129.5M |
BetterLife Pharma Inc does not pay a dividend. | |
Beta | 1.37 |
EPS | $-0.04 |
Book Value | $-0.09 |
P/E Ratio | -2.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
